Ajooni Biotech Intrinsic Value
AJOONI Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹2.40 | ₹1.92 - ₹2.88 | -43.0% | EPS: ₹0.20, Sector P/E: 12x |
| Book Value Method | asset | ₹10.53 | ₹9.48 - ₹11.58 | +150.1% | Book Value/Share: ₹25.88, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹8.42 | ₹7.58 - ₹9.26 | +100.0% | Revenue/Share: ₹37.94, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹8.42 | ₹7.58 - ₹9.26 | +100.0% | EBITDA: ₹7.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹10.53 | ₹8.42 - ₹12.64 | +150.1% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹1.28 | ₹1.15 - ₹1.41 | -69.6% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1.72 | ₹1.55 - ₹1.89 | -59.1% | Revenue Growth: 14.9%, Adj P/E: 8.6x |
| Graham Defensive Method | conservative | ₹10.79 | ₹9.71 - ₹11.87 | +156.3% | EPS: ₹0.20, BVPS: ₹25.88 |
Want to compare with current market value? Check AJOONI share price latest .
Valuation Comparison Chart
AJOONI Intrinsic Value Analysis
What is the intrinsic value of AJOONI?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Ajooni Biotech (AJOONI) is ₹8.42 (median value). With the current market price of ₹4.21, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹1.28 to ₹10.79, indicating ₹1.28 - ₹10.79.
Is AJOONI undervalued or overvalued?
Based on our multi-method analysis, Ajooni Biotech (AJOONI) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 31.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.08 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 4.5% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 3.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.36x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Ajooni Biotech
Additional stock information and data for AJOONI
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-18 Cr | ₹-27 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹23 Cr | ₹23 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹-6 Cr | ₹-14 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹4 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹1 Cr | ₹-1 Cr | Positive Operating Cash Flow | 6/10 |